Homeland Security

GenVec Announces Increased Funding for FMD Vaccine Program from the U.S. Department of Homeland Security

Published in Medical Letter on the CDC and FDA, September 23rd, 2007

GenVec, Inc. (Nasdaq:GNVC) announced that it has executed the first option period from the previously announced agreement with the U.S. Department of Homeland Security (DHS) that will provide $5.6 million over the next 12 months to support the development of vaccines for the prevention of foot-and-mouth disease (FMD).

This funding increases the total value of GenVec's three-year agreement from $15.2 million to $17.5 million. The additional funds will be used primarily for expanded development activities. Under the terms of the agreement, GenVec is responsible for the development, production and regulatory approval of the vaccine, while DHS is responsible for conducting...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2007-09-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry